NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financi... (in December 2008. This patent will expi...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results

Date:4/1/2009

in December 2008. This patent will expire in 2026. NovaBay has recently filed additional patent applications that cover compositions of matter of additional Aganocide compounds, methods of use and formulations, and is preparing further applications in other areas.

Financial Results

Fourth Quarter 2008 Financial Results

License and collaboration revenue for the fourth quarter of 2008 increased 44% to $2.2 million from $1.5 million for the fourth quarter of 2007. License and collaboration revenue consists of the amortization of the upfront technology access fees previously paid, and reimbursements for the funding of research and development activities.

The net loss for the fourth quarter of 2008 was $(1.5) million, or $(0.07) per share, compared to a net loss of $(1.4) million, or $(0.09) per share, reported for the fourth quarter of 2007.

Research and development expenses for the quarter ended December 31, 2008 totaled $3.3 million, compared to $1.8 million for the quarter ended December 31, 2007. The increase was largely due to the timing of pre-clinical and clinical trials.

General and administrative expenses for the quarter ended December 31, 2008 were $0.5 million, compared to $1.2 million in the comparable 2007 period.

NovaBay ended the quarter and year with $12.1 million in cash and cash equivalents.

Full Year 2008 Financial Results

For the full year 2008, license and collaboration revenue totaled $6.7 million, compared to $5.9 for the year 2007.

NovaBay reported a net loss of $(8.1) million, or $(0.38) per share, for the full year 2008, compared to a net loss of $(5.4) million, or $(0.60) per share, for the full year 2007.

Research and development expenses for the full year 2008 were $9.6 million compared with
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/15/2009)... The Joint BioEnergy Institute (JBEI), one of three Department ... AbsoluteProof trusted time-stamping service to protect its valuable intellectual ... ... Reston, VA (PRWEB) December 15, 2009 -- Surety, ... protection solutions , today announced that the Joint BioEnergy ...

(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, ... Market Forecasts to 2015, Pipeline Analysis and ... ,, Summary ... research "The Future of Orphan Diseases Therapeutics ...

(Date:12/15/2009)... have been developed and are opening up a new area ... NeedleProbes’ cylindrical geometry enables researchers to measure surface tension, contact ... a single force distance curve. , ... ... NeedleProbes are enabling unique measurements at the liquid/air interface. ...

(Date:12/15/2009)... 15 The Center for Business ... is pleased to announce the full agenda ... and Reporting Congress . The forum will ... March 16-17, 2010. ,, Over 1,500 senior-level ... attended this premier event since its inception, ...

[0] Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM [0] CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress

... board and scientific research, collaborators, LineaGen is leveraging new funding ... Utah,s proven biomarker, discovery platform for commercializing first-in-class molecular diagnostic ... ... Dec. 19 LineaGen Inc.,( http://www.LineaGen.com ), a biomarker discovery company ...

... treatment could ... benefit patients, DOYLESTOWN, ... partnership with Drexel University College of,Medicine, think they may have discovered ... fibrosis and cirrhosis, which,afflict more than 5 million Americans. People with ...

... in Europe to Offer up to Six Months of Pain Relief ... in ... ) announced today that it has been granted European approval,through a CE mark ... in the European Union to provide up to,six months of proven pain relief ...

Other Biology Technology:LineaGen Inc. Launches With Close of $5.8 Million Series A Funding Round 2 LineaGen Inc. Launches With Close of $5.8 Million Series A Funding Round 3 LineaGen Inc. Launches With Close of $5.8 Million Series A Funding Round 4 Possible New Way to Detect, Monitor Liver Disease Without Painful Liver Biopsy 2 Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM) 2 Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM) 3 Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM) 4 Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM) 5

LineaGen Inc. Launches With Close of $5.8 Million Series A Funding Round Possible New Way to Detect, Monitor Liver Disease Without Painful Liver Biopsy Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)

(Date:12/16/2009)... US Secretary of Energy Steven Chu announced today the ... outstanding contributions in research and development supporting the Department ... named today will receive a gold medal, a citation ... a ceremony in Washington, DC early next year., "The ... economic and energy security of the United States are ...

(Date:12/16/2009)... get psyched up for contests, but when these rituals ... down before and during events, they could be causing ... for the symptoms of an injury, not the injury ... focuses on musculoskeletal health and sports medicine. "They may ... certain level, but pain occurs for a reason. It ...

(Date:12/16/2009)... University of Maryland School of Medicine researcher will lead ... most prominent scientists in the field of stem cell ... Preventive Medicine, was chosen by the National Heart, Lung ... this consortium of national experts, which will be called ... will be funded by a $30 million grant over ...

Breaking Biology News(10 mins):Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2 NSAIDs: Take 'em early and often when competing? Think again 2 University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2 University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3 Partnership for Prescription Assistance Prepared to Help Midwestern Workers Hurt by Recession 59220 1 Partnership for Prescription Assistance Prepared to Help Midwestern Workers Hurt by Recession 59220 2 Partnership for Prescription Assistance Prepared to Help Midwestern Workers Hurt by Recession 59220 3 Partnership for Prescription Assistance Prepared to Help Midwestern Workers Hurt by Recession 59220 4 Saks Key to the Cure Shopping Weekend to Benefit Henry Ford Health System 59218 1 Czura Thornton Announces Intention to Acquire Global Central Laboratory Business of MDS Pharma Services 59216 1 Czura Thornton Announces Intention to Acquire Global Central Laboratory Business of MDS Pharma Services 59216 2

[0] Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners [0] NSAIDs: Take 'em early and often when competing? Think again [0] University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium

... Officers ... Informed and In Touch, WALL, N.J., Nov. ... finger-based biometric,identification and wireless public safety, was featured in a recent,televised ... 5, the ABC affiliate in Oklahoma City. The,November 18th report highlighted ...

... to double by 2030, the scale of which is significant in ... the essential role of coal in Chinas energy system, it is ... The British Geological Survey (BGS) attended the launch of the Near ... The aim of this study is to look at the feasibility ...

... Carnegie Mellon University graduate engineering students Shahzeen Attari, Ines ... are first-place winners in a letter-writing competition called Tomorrows ... ... Johnson Controls Inc., asked students to demonstrate their awareness ...

Other Biology News:BIO-key(R) PocketCop(R) Project 'Leading the Nation' According to Televised Report 2 UK scientists lead China closer to carbon capture and storage 2 Carnegie Mellon students win contest 2 Carnegie Mellon students win contest 3

BIO-key(R) PocketCop(R) Project 'Leading the Nation' According to Televised Report UK scientists lead China closer to carbon capture and storage Carnegie Mellon students win contest

... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (Z71,487-9) or contact customer ... centre neck 100 mm, No. of ...

... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...

... Aph-1a (Aph-1aL,S Loop 92-115), O2F1 Affinity ... a multiprotein complex consisting of presenilin, ... proteins are necessary for full proteolytic ... cleavage of a number of integral ...

... Glutathione-S-transferases (GSTs) are a group of enzymes ... xenobiotics in mammals. The enzymes protect cells ... of the glutathione to electrophilic xenobiotics, and ... and toxic effects of the compounds. GST ...

Biology Products:

Corning Proculture Spinner Flask,15L,Vertical S/Arm, No. Of S/A 4,Cent Neck 100mm from Sigma-Aldrich Blasticidin S HCl from Invitrogen Rabbit Anti-Aph-1aL, S Loop (92-115) Polyclonal Antibody, Unconjugated from Covance Research Products, Inc Glutathione-S-Transferase (GST) Colorimetric Assay Kit from Sigma-Aldrich

NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financi...(in December 2008. This patent will expi...)